Related Experiment Videos
Digoxin toxicity in a premature infant: treatment with Fab fragments of digoxin-specific antibodies
Pediatric Cardiology
|January 1, 1985
Insights
The first use of Fab fragments successfully treated digoxin toxicity in a premature infant. This groundbreaking treatment resolved severe arrhythmias and demonstrated significant efficacy in a critical neonatal case.
Area of Science:
- Neonatal Medicine
- Cardiology
- Pharmacology
Background:
- Digoxin toxicity presents a significant risk, particularly in premature infants with compromised renal function.
- Cerebral arteriovenous malformations can necessitate digoxin therapy for heart failure, increasing toxicity risk.
- Severe arrhythmias indicate a critical state of digoxin toxicity.
Observation:
- A premature infant experiencing severe arrhythmias due to digoxin toxicity was treated 18 hours after symptom onset.
- The infant had renal failure, complicating the management of digoxin toxicity.
- Digoxin toxicity developed despite the administration of accepted therapeutic doses.
Findings:
- Treatment with digoxin-specific antibody fragments (Fab fragments) yielded dramatic positive results.
- Fab fragments effectively reversed the life-threatening digoxin toxicity.
- The infant's severe arrhythmias were resolved following Fab fragment administration.
Implications:
- Fab fragments represent a crucial therapeutic option for managing digoxin toxicity in neonates.
- This case highlights the potential for rapid and effective intervention in critical digoxin poisoning.
- Further research into Fab fragment use in pediatric populations with digoxin toxicity is warranted.
Abstract:
The first use of Fab fragments to treat digoxin toxicity in a premature infant with renal failure, 18 h after the onset of severe arrhythmias, is reported with dramatic results. The development of digoxin toxicity in the context of accepted therapeutic dosing to treat heart failure due to a cerebral arteriovenous malformation is discussed.